Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 731

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 7
Chunk 731
---
 Operations at BioMarin Pharmaceutical Inc., where he spent 20 years in various capacities overseeing the
manufacturing, process development, quality, analytical chemistry, logistics and engineering departments. Prior to BioMarin, Dr. Baffi
worked for Genentech, Cooper BioMedical and Becton Dickinson Research Center. He currently serves on the board for the National Institute
for Bioprocessing Research & Training (“NIBRT”) and Neurogene Inc. Dr. Baffi received a Ph.D., M. Phil and a B.S. in biochemistry
from the City University of New York and an M.B.A. from Regis University.

The Board concluded that Dr. Baffi should serve as
a director because of his extensive drug development and commercialization experience with biotechnology products.

Robert Garnick, Ph.D. Dr. Garnick was nominated
to serve as a director on August 21, 2020. Dr Garnick holds a Ph.D. in Natural Products / Organic Chemistry from Northeastern University
in Boston. He was a Senior V.P. of Regulatory, Quality and Compliance at Genentech when he left in 2008. Dr. Garnick started at Genentech
in 1984 and was directly responsible for the approval of a number of biotechnology products including such blockbusters as Rituxan®,
Herceptin® and Avastin®. Dr. Garnick left Genentech in 2008 and founded Lone Mountain Biotechnology and Medical Devices Inc.,
a consulting company. Dr Garnick was co-founder of Bioanalytix in Boston and an early investor in Stemcentrx in San Francisco. Dr. Garnick
has extensive drug and biologics development experience and was a frequent lecturer on biotechnology products and processes.

The Board concluded that Dr. Garnick should serve
as a director because of his extensive drug development and commercialization experience with biotechnology products.

Paul Lytle. Mr. Lytle was nominated to serve
as a director on August 21, 2020, and was appointed Executive Vice President, Chief Financial Officer on August 31, 2020. Effective June
1, 2024, Mr. Lytle reduced his time commitment to part-time status to provide no more than 8 hours of service per month. Mr. Lytle has
over 25 years of finance and accounting experience, including over 20 years of public company experience and CFO experience in the field
of biotechnology and medical devices. Mr.